List view / Grid view
2 September 2014 | By Roche
The cobas 6800/8800 Systems offer advanced performance with next generation donor screening assays...
1 September 2014 | By Roche
Roche announced that it has commenced a cash tender offer for all outstanding shares of common stock of InterMune, Inc. at a price of US$74.00 per share...
26 August 2014 | By Roche
Roche and InterMune, Inc. announced they have entered into a definitive merger agreement for Roche to fully acquire InterMune at a price of US$ 74.00 per share in an all-cash transaction...
15 August 2014 | By Roche
Avastin is the first biologic medicine approved in combination with chemotherapy to help women with this type of cancer live longer than with chemotherapy alone...
6 August 2014 | By Roche
First new treatment option for women in Europe in more than 15 years for most difficult to treat form of ovarian cancer...
5 August 2014 | By Roche
Roche announced that it has agreed to acquire Santaris Pharma, a privately held biopharmaceutical company based near Copenhagen, Denmark...
29 July 2014 | By Roche
Roche announced that the European Commission has approved Gazyvaro (obinutuzumab) in combination with chlorambucil chemotherapy...
28 July 2014 | By AstraZeneca
AstraZeneca announced it has entered into collaboration with Roche to develop a plasma-based companion diagnostic test to support AZD9291...
24 July 2014 | By Roche
Pharmaceutical giant Roche delivers its first-half results for 2014...
17 July 2014 | By Roche
Roche presented data from two phase II studies investigating whether crenezumab can delay cognitive and functional decline in people with mild-to-moderate Alzheimer’s disease...
15 July 2014 | By Roche
Roche announced that the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application and granted Priority Review for Avastin (bevacizumab) plus chemotherapy for the treatment of women with persistent, recurrent or metastatic cervical cancer...
14 July 2014 | By Roche
Roche announced that the Phase III coBRIM study met its primary endpoint...
4 July 2014 | By Roche
Data showed that over 90 percent of Japanese people in the study responded to treatment with alectinib...
2 July 2014 | By Roche
Acquisition of Phase I program offers a potential new approach for hormone receptor-positive breast cancer...
30 June 2014 | By Roche
Roche announced the launch of cobas® 6500, a fully automated urine testing system that consists of two modular analyzers combining urine strip testing and digital urinary microscopy...
